Skip to content
OpenCapital
Get started

Zevra Therapeutics, Inc. ZVRA Quick ratio

Quick ratio at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
4.2×+0.7×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
1.9×-0.4×
XER
Xeris Biopharma Holdings, Inc.XERS
1.5×+0.3×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
0.9×-0.6×
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.1×+8.4×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
22.1×+2.2×

Other financials

Income statement

See full
Revenue$36.2M+77.5%
Gross profit$34.3M+80.1%
Operating income$52.1M+1,073%
Net income$37.9M+1,323%
EPS (diluted)$0.60+1,100%

Balance sheet

See full
Cash & equivalents$95.6M+156%
Total debt$1.1M-98.1%
Total equity$205.8M+402%
Total assets$278.6M+61.3%

Cash flow

See full
Operating cash flow$6.1M+175%
CapEx$35.0K-64.6%
Free cash flow$6.1M+173%

Valuation

See full
Market cap$773.23M+56.4%
Enterprise value$678.78M+30.8%
P/E6.2×—
P/S6.3×-5.9×

Profitability

See full
Gross margin86.1%+7.2pp
Operating margin-103.9%-43.0pp
Net margin101.6%+60.1pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity100.7%+60.3pp
Debt / equity0×-1.5×
Current ratio4.9×+1.9×

Where this comes from

Calculated from Zevra Therapeutics, Inc.’s reported figures.

quick assets/total current liabilities=4.9×

Based on the most recent quarter.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s quick ratio?
Zevra Therapeutics, Inc. (ZVRA) reported quick ratio of 4.9× in Q1 2026.
How has Zevra Therapeutics, Inc.'s quick ratio changed year-over-year?
Zevra Therapeutics, Inc.'s quick ratio increased by 85.9% year-over-year, from 2.6× to 4.9×.
What is the long-term trend for Zevra Therapeutics, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s quick ratio has grown at a 38.4% compound annual growth rate (CAGR), from 1.1× to 5.7×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.